Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Via Archirafi 32, 90123, Palermo, Italy.
Telethon Institute of Genetics and Medicine (TIGEM), Campi Flegrei 34, 80078, Pozzuoli, NA, Italy.
Eur J Med Chem. 2019 Oct 15;180:430-448. doi: 10.1016/j.ejmech.2019.07.037. Epub 2019 Jul 15.
Deletion of phenylalanine at position 508 (F508del) in the CFTR protein, is the most common mutation causing cystic fibrosis (CF). F508del causes misfolding and rapid degradation of CFTR protein a defect that can be targeted with pharmacological agents termed "correctors". Correctors belong to various chemical classes but are generally small molecules based on nitrogen sulfur or oxygen heterocycles. The mechanism of action of correctors is generally unknown but there is experimental evidence that some of them can directly act on mutant CFTR improving folding and stability. Here we overview the characteristics of the various F508del correctors described so far to obtain indications on key chemical structures and modifications that are required for mutant protein rescue.
CFTR 蛋白第 508 位苯丙氨酸缺失(F508del)是导致囊性纤维化(CF)最常见的突变。F508del 导致 CFTR 蛋白错误折叠和快速降解,这一缺陷可以用称为“校正剂”的药物靶向治疗。校正剂属于各种化学类别,但通常是基于氮、硫或氧杂环的小分子。校正剂的作用机制通常未知,但有实验证据表明,其中一些可以直接作用于突变型 CFTR,改善其折叠和稳定性。在这里,我们综述了迄今为止描述的各种 F508del 校正剂的特性,以获得有关挽救突变蛋白所需的关键化学结构和修饰的指示。